[
    [
        {
            "time": "",
            "original_text": "C XO 股价调整后是否再次上车机会？持续重点推荐药明康德、凯莱英等",
            "features": {
                "keywords": [
                    "股价调整",
                    "上车机会",
                    "药明康德",
                    "凯莱英"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "C XO 股价调整后是否再次上车机会？持续重点推荐药明康德、凯莱英等",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "甲贝医药完成数千万元Pre-A轮融资",
            "features": {
                "keywords": [
                    "甲贝医药",
                    "融资",
                    "Pre-A轮"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "甲贝医药完成数千万元Pre-A轮融资",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]